Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J

Iwamoto, Yukihide; Tanaka, Kazuhiro; Isu, Kazuo; Kawai, Akira; Tatezaki, Shin-ichiro; Ishii, Takeshi; Kushida, Kazuyoshi; Beppu, Yasuo; Usui, Masamichi; Tateishi, Akio; Furuse, Kiyoo; Minamizaki, Takeshi; Kawaguchi, Noriyoshi; Yamawaki, Shinya

doi:10.1007/s00776-009-1347-6

Cited by 105 publications

(73 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, we included 1070 patients (557 in the training set and 513 in the validation set) who had a complete set of data for prognostic variables. Among these patients, the chemotherapy regimen in the Japanese cohort was based on a protocol composed of methotrexate, doxorubicin, and cisplatin (MAP) or MAP plus ifosfamide 20, 21. The majority of the patients in the Korean cohort were treated with MAP 22…”

Section: Resultsmentioning

confidence: 99%

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study

Ogura

Fujiwara

Yasunaga

et al. 2015

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUNDIn this era of individualized cancer treatment, data that could be applied to predicting the survival of patients with osteosarcoma are still limited because of the rarity of the disease and the difficulty in accumulating a sufficient number of patients. Therefore, a multi‐institutional collaboration was implemented to develop and externally validate nomograms that would predict metastasis‐free survival (MFS) and overall survival (OAS) for patients with nonmetastatic osteosarcoma.METHODSThis study retrospectively examined 1070 patients treated with neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma. Data from Japanese patients (n = 557) were used to develop multivariate nomograms based on Cox regression. Six clinical and pathologic variables were built into nomograms estimating the probability of MFS and OAS 3 and 5 years after diagnosis. The model was internally validated for discrimination and calibration with bootstrap resampling and was externally validated with an independent patient cohort from Korea (n = 513).RESULTSA patient's age, tumor site, and histologic response were found to have a stronger influence on MFS and OAS in the model than sex, tumor size, or pathologic fracture. The nomograms and calibration plots based on these results well predicted the probability of MFS (concordance index, 0.631) and OAS (concordance index, 0.679). The concordance indices for external validation were 0.682 for MFS and 0.665 for OAS.CONCLUSIONSThe nomograms were externally validated and verified to be useful for the prediction of MFS and OAS and for the assessment of the postoperative prognosis. They can be used for counseling patients and for establishing appropriate surveillance strategies after surgery. Cancer 2015;121:3844–3852. © 2015 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study

Ogura

Fujiwara

Yasunaga

et al. 2015

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chemotherapeutic regimens have evolved substantially and rapidly over the last 20 years and continue to be highly individualized based on unique patient and tumor characteristics, along with institutional experience. In recent years, multiagent chemotherapy using methotrexate, doxorubicin, cisplatin, and ifosfamide has become a standard of care for osteosarcoma [13]. Secondly, we could not analyze pathological findings due to a lack of accurate data.…”

Section: Discussionmentioning

confidence: 99%

Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy

Matsubara

Mori

Kinoshita

et al. 2015

Journal of Respiratory Medicine

View full text Add to dashboard Cite

.Purpose. To identify prognostic factors for metastatic osteosarcoma patients and establish indication for repeat metastasectomy. Methods. Data from 37 patients with pulmonary metastasis from osteosarcoma who underwent metastasectomy in our institute from 1979 to 2013 were retrospectively reviewed. Results. Prognostic factors analyzed were age, sex, maximal diameter of the tumor at first pulmonary metastasectomy, total number of resected pulmonary metastases at first metastasectomy, number of surgeries, and disease free interval. In our analysis, characteristics associated with an increased overall survival were age > 15 years and fewer metastases (≤3). Of the 37 patients, 13 underwent repeat metastasectomy after the first metastasectomy. Of the 7 patients that underwent only two metastasectomies, three remained disease-free. In contrast, all six patients that underwent three or more metastasectomies died of relapse. Patients who had five or less lesions at second metastasectomy showed better survival compared to those who had six or more lesions. Conclusion. Age > 15 years and number of metastases at first metastasectomy were independent prognostic factors. Metastasectomy may provide curative treatment even in cases requiring repeat surgery. The number of metastases at second metastasectomy may be a potential predictor of the need for repeat surgery.

show abstract

“…In Japan, neoadjuvant chemotherapy for osteosarcoma using the above protocols has led to dramatic improvements in the survival rate (19). However, recurrences, metastasis, and drug resistance often occur.…”

Section: Discussionmentioning

confidence: 99%

Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells

Muramatsu

Matsui

Deie

et al. 2017

View full text Add to dashboard Cite

Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J

Cited by 105 publications

References 21 publications

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study

Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy

Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells

Contact Info

Product

Resources

About